Jacob W. Stahl is counsel in the firm’s New York office and a member of the firm’s Litigation Department. His practice focuses on representing clients on healthcare-related issues, including commercial litigation, administrative disputes and compliance and regulatory advice. He also represents clients in the areas of mass tort, products liability, general commercial litigation and white collar criminal defense.
Mr. Stahl received an LL.M. in Global Health Law from Georgetown University Law Center in 2018, Dean’s List, with Distinction, Thomas Bradbury Chetwood, S.J. Prize, and a J.D. from Harvard Law School cum laude in 2005. He received a B.A. from the University of Pennsylvania, summa cum laude, Phi Beta Kappa in 2001. Mr. Stahl joined the firm in 2005.
Mr. Stahl is a member of the New York City Bar Health Law Committee. He is the co-author of numerous articles, including “The SEC/FDA Nexus: Best Practices for Publicly Traded Life Sciences Companies” Bloomberg Law(November, 2018); “D.C. Circuit Court Decision May Help Level the Playing Field for TCPA Defendants” Bloomberg BNA (April, 2018); “A Look at Recent Efforts to Contain Health Care Costs,” Law360 (January, 2018); “How Tax Reform Could Impact the Health Care Industry,” Law360 (November, 2017); “How Section 1332 Waivers Could Impact Health Care Reform,” Law360 (July, 2017); “Health Care Winners And Losers From The Better Care Act,” Law360 (June, 2017); “Shining A Light On GOP Plan For Health Care Reform,” Law360(March, 2017); “The Outlook For The Pharmaceutical Industry Under Trump,” Law360 (January, 2017); “The Outlook On Drug Pricing: At What Cost?” Law360 (December, 2016); “A Walk in the Park Shouldn’t Lead to Jail Time: Recent Decisions Explain Why Incarceration Is Never Appropriate for ‘Responsible Corporate Officers’ Who Lack Criminal Intent,” Bloomberg BNA Pharmaceutical Law & Industry Report (October, 2016); “FDA’s New Guidance On Cybersecurity For Medical Devices: Important Lessons For The Entire Healthcare Industry,” Bloomberg BNA Health IT Law & Industry Report (April, 2016); “Canada Vs. US Product Liability: Recent Developments,” Law360 (January, 2016); “Avoiding And Defeating Securities Fraud Actions Against Clinical-Stage Biopharmaceutical Companies,” Bloomberg BNA Life Sciences Law & Industry Report (July, 2015); “Food For Thought: Corporate Executives On Notice That DOJ Will Seek To Hold Them Criminally Liable for Contaminated Food Outbreaks And Product Failures,” Bloomberg BNA’s White Collar Crime Report (November, 2014); “It’s A Hard-Knock Life: The Rough-And-Tumble Fight Over Orphan Drug Pricing,” Bloomberg BNA’s Pharmaceutical Law & Industry Report (November, 2014); “DOJ Proposal Shows Focus on Individuals in Corporate Crime,” Law360 (September, 2014); “Compliance Corner: The Clock Is Ticking: 60-Day Rule and FCA Liability for Overpayments,” Bloomberg BNA’s Health Care Fraud Report (September, 2014); “Vicarious Criminal Liability in the Executive Suite for Problems on the Manufacturing Floor,” Bloomberg BNA’s Pharmaceutical Law & Industry Report (April, 2014) and “Enforcement without Guidance: The FDA’s Policing of Online Pharmaceutical Advertisements and Communications,” Bloomberg BNA Pharmaceutical Law & Industry Report (December, 2013).
- HCA Healthcare in its $1.5 billion acquisition of Mission Health, a nonprofit North Carolina health system.
- Clayton, Dubilier & Rice in its joint investment with Cardinal Health in naviHealth, the largest manager of post-acute benefits for health plans and a leading value-based care partner to health systems and providers.
- TPG Capital and Welsh, Carson, Anderson & Stowe, with Humana, in their $1.4 billion acquisition of Curo Health Services.
- TPG Capital and Welsh, Carson, Anderson & Stowe in the $4.1 billion acquisition of Kindred Healthcare.
- Sawai Pharmaceutical in its $1.5 billion acquisition of the generic pharmaceuticals business of Upsher-Smith Laboratories.
- A major hospital corporation in a wide variety of commercial matters, including a breach of contract action arising out of the purchase of a healthcare system and administrative disputes involving medical center licensing.
- Bristol-Myers Squibb in defending against a $3.4 billion contract and tort claim by generic drug manufacturer Apotex, winning a unanimous jury verdict of no liability.
- American Airlines in litigation arising out of the September 11, 2001 terrorist attacks, resulting in a recent trial victory establishing that World Trade Center Properties could not recover from American any of the nearly $5 billion it was seeking beyond already received insurance recoveries. Previous related wins have included dismissals of environmental litigation arising out of the attacks and multiple successful partial summary judgment and Daubert motions.
- Georgetown University Law Center, 2018, LL.M.
- Harvard Law School, 2005, J.D.
- University of Pennsylvania, 2001, B.A.
- New York
Rate : $$$$